Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
Background. The problem of childhood obesity remains relevant for modern healthcare. Effective treatment models for this disease are needed with the inclusion of new therapeutic agents, including GLP-1 receptor agonists such as liraglutide (approved from the age of 12). However, its safety and effic...
Saved in:
Main Authors: | Olga P. Kovtun, Margarita A. Ustiuzhanina, Svyatoslav I. Solodushkin, Lyudmila V. Kovalchuk, Kira Ya. Zaslavskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Union of pediatricians of Russia
2025-05-01
|
Series: | Педиатрическая фармакология |
Subjects: | |
Online Access: | https://www.pedpharma.ru/jour/article/view/2596 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01) -
Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01) -
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01) -
Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01) -
Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025-06-01)